Ursodeoxycholic Acid in Cystic Fibrosis-Related Liver Disease: A Systematic Review

Elborn JS , Shale DJ , Britton JR . Cystic fibrosis: current survival and population estimates to the year 2000. Thorax 1991; 46: 881–5.

Scott-Jupp R , Lama M , Tanner MS . Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991; 66: 698–701.

Oppenheimer EH , Esterly JR . Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975; 86: 683–9.

Roy CC , Webbed AM , Morin CL Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr 1992; 1: 469–78.

Cohn JA , Strong TV , Piccolo MR , Cairn AC , Colleens FS , Fit DIG . Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 106: 1857–64.

Tanner MS . Liver and biliary problems in cystic fibrosis. J R Soc Med 1992; 85(Suppl. 19): 20–4.

O'Brien S , Keogan M , Casey M , Duffy G , McErlean D , Fitzgerald MX , Hegarty JE . Biliary complications of cystic fibrosis. Gut 1992; 33: 387–91.

Colombo C , Apostolo MG , Ferrari M Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994; 124: 393–9.

Noble-Jamieson G , Valente J , Barnes ND Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 1994; 71: 349–52.

Tanner MS . Liver disease in cystic fibrosis. Arch Dis Child 1995; 72: 281–4.

Carry H. Abdominal radiology in cystic fibrosis. J R Soc Med 1995; 88(Suppl. 25): 18–23.

O'Connor PJ , Southern KW , Bowler IM , Irving HC , Robinson PJ , Littlewood JM . The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology 1996; 23: 281–7.

Erlinger S , Dumont M. Influence of ursodeoxycholic acid on bile secretion. In: Paumgartner G , Stiehl A , Barbara L , eds. Strategies for the treatment of hepatobiliary disease. Dordrecht: Kluwer Academic, 1990;pp. 35–42.

Poupon RE , Poupon R , Balkau B , and the UDCA-PBC study group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342–7.

Beuers U , Spengler U , Kruis W Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16: 707–14.

Colombo C , Setchell KDR , Podda M Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990; 117: 482–9.

Colombo C , Crosignani A , Assaisso M Ursodeoxycholic acid in cystic fibrosis-associated liver disease: a dose–response study. Hepatology 1992; 16: 924–30.

British National Formulary 1996; 31: 55.

The Cochrane Collaboration Handbook 1994; Section 1.

The Cochrane Database of Systematic Reviews. In: The Cochrane Library. 1996, Issue 3. London: BMJ Publishing Group.

The Cochrane Controlled Trials Register. In: The Cochrane Library. 1996, Issue 3. London: BMJ Publishing Group.

Cochrane Collaboration Handbook 1994; Section V.

Schulz KF , Chalmers I , Hayes RJ , Altman DG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408–12.

Colombo C , Podda M , Battezzati PM Ursodeoxycholic acid for cystic fibrosis-associated liver disease; final report of a multicenter trial. Hepatology 1993; 18: 142A.

Colombo C , Battezzati PM , Santini B Treatment with ursodeoxycholic acid for patients with cystic fibrosis and liver disease. In: Escobar H , Baquero F , Suarez L eds. Clinical ecology of cystic fibrosis. Amsterdam: Elsevier Science Publishers BV 1993.

Colombo C , Battezzati PM , Santini B Ursodeoxycholic acid (UDCA) for liver disease associated with cystic fibrosis (CF): a double-blind multicenter trial. Proceedings of 18th European Cystic Fibrosis Conference. 1993.

Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A, and the Italian group for the ‘Study of ursodeoxycholic acid in cystic fibrosis’. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996; 23: 1484–90.

Colombo C , Setchell KDR , Podda M , Crosignani A , Assaisso ML , Giunta A. Ursodeoxycholic acid in cystic fibrosis-associated liver disease: a dose–response study. Proceedings of 17th European Cystic Fibrosis Conference. 1991.

Bittner P , Seiler T , Ott H , Posselt H-G , Margdorf K , Kawinkel M. Therapeutical approach of ursodeoxycholic acid in cystic fibrosis and hepatopathy. Proceedings of 16th European Cystic Fibrosis Conference 1989.

Narkewicz MR , Sokol RJ , Lear JL , Wagener JS , Accurso FJ . Effect of ursodeoxycholic acid (UDCA) therapy for CF liver disease on indirect tests of hepatic function. Proceedings of 8th North American Cystic Fibrosis Conference. Pediatr Pulmonol 1994; 310: 342.

Merli M , Bertasi S , Servi R Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial. J Pediatr Gastroenterol Nutr 1994; 19: 198–203.

O'Brien S , Fitzgerald MX , Hegarty JE . A controlled trial of ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatol 1992; 4: 857–63.